CNS Pharma stockholders approve reverse split (1:2 to 1:50) and warrant repricing

CNS Pharmaceuticals, Inc.

Reverse split authorized at ratio between 1-for-2 and 1-for-50; passed with 7,873,677 votes for, 3,121,776 against, 314,908 abstain.
Warrant repricing approved: new exercise price lower of $1.13 per share or closing price on approval date; 1,458,915 for, 1,106,009 against, 171,894 abstain.
Adjournment authorization passed: 8,022,415 for, 2,904,712 against, 383,234 abstain.
Meeting held Nov 26, 2024; quorum of 11,310,361 shares (33.82% of 33,446,403 outstanding) present.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.